Commentary
The purpose of this study by H. Fennoun et al. (University Hospital, Casablanca, Morocco) was to determine the interest of hepatic steatosis index in the detection of hepatic steatosis in patients with type 2 diabetes in order to establish an appropriate screening program of this disease in the population of diabetics hospitalized in Morocco.
This was a cross-sectional study involving 281 type 2 diabetics. The hepatic steatosis index score of> 36 predicted the presence of fatty liver.
Prevalence of NAFLD was 45.2% based on the HSI score > 36 (sensitivity 93%), consistent with the liver ultrasound findings (47.7% of cases). The sensitivity of HSI was 89.55%.
The hepatic steatosis index is a simple non-invasive tool and a validated screening for NAFLD, with performance characterized by an AUROC of 0.81. HSI score < 30 excludes hepatic steatosis. A score > 36 has a. In our study, the sensitivity of hepatic steatosis index was 89.55% in this study.
